OEL Fastrac Catalog

Astaxanthin is a keto-carotenoid within a group of chemical compounds known as carotenones or terpenes. Astaxanthin is a metabolite of zeaxanthin and canthaxanthin, containing both hydroxyl and ketone functional groups. Astaxanthin is classified as a xanthophyll, but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has been shown to mediate antioxidant and anti-inflammatory actions. It may be found in fish feed and some other animal feed as a color additive. Astaxanthin is taken by mouth for treating Alzheimer's disease, Parkinson's disease, stroke, high cholesterol, age-related macular degeneration (age-related vision loss), and for preventing cancer. It is also used for metabolic syndrome, which is a group of conditions that increase the risk of heart disease, stroke, and diabetes. It is also used for improving exercise performance, decreasing muscle damage after exercise, and decreasing muscle soreness after exercise. Also, astaxanthin is taken by mouth for carpal tunnel syndrome, dyspepsia, male infertility, symptoms of menopause, and rheumatoid arthritis.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Astaxanthin, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.